Gh Research Plc (GHRS)
NASDAQ:GHRS
Top Page
GH Research
(NASDAQ:GHRS)
Select Model
Select Model
Rating:50Neutral
Price Target:
$13.00
▼(-11.68% Downside)
Action:ReiteratedDate:03/06/26
The score is held down primarily by pre-revenue financials with widening losses and continued cash burn, partially offset by a very low-leverage balance sheet. Technicals are neutral-to-mildly supportive (price above longer-term averages with neutral momentum), while valuation is constrained by negative earnings and no dividend data.
Positive Factors
Peer-reviewed Phase 2b validation
A peer-reviewed Phase 2b publication in JAMA Psychiatry provides durable scientific validation of GH001's efficacy and safety signals. This strengthens credibility with regulators, clinicians and potential partners, supporting design and enrollment for global Phase 3 trials and long-term adoption if pivotal results replicate.
Negative Factors
Pre-revenue with widening net losses
The company remains pre-commercial and losses have accelerated, meaning no product revenue to offset R&D and G&A. Over the medium term this necessitates external funding or partnerships; failure to secure favorable financing terms would dilute shareholders or constrain development pace and strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Peer-reviewed Phase 2b validation
A peer-reviewed Phase 2b publication in JAMA Psychiatry provides durable scientific validation of GH001's efficacy and safety signals. This strengthens credibility with regulators, clinicians and potential partners, supporting design and enrollment for global Phase 3 trials and long-term adoption if pivotal results replicate.
Read all positive factors
GH Research (GHRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$913.07M
Dividend YieldN/A
Average Volume (3M)204.32K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth8.16%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding62,029,396
10 Day Avg. Volume151,652
30 Day Avg. Volume204,325
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.54K
Enterprise Value/Ebitda-13.04
Forecast
1Y Price Target
$41.29Price Target Upside180.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.44
Revenue Forecast (FY)N/A
GH Research Business Overview & Revenue Model
Company Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therap...
How the Company Makes Money
null...
GH Research Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -335.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -60.34M | -38.60M | -35.21M | -22.41M | -9.17M |
| Net Income | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M |
Balance Sheet | |||||
| Total Assets | 288.23M | 188.27M | 226.30M | 254.36M | 279.92M |
| Cash, Cash Equivalents and Short-Term Investments | 280.71M | 149.32M | 161.56M | 165.96M | 276.78M |
| Total Debt | 512.00K | 624.00K | 974.00K | 0.00 | 0.00 |
| Total Liabilities | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M |
| Stockholders Equity | 279.70M | 178.95M | 218.97M | 249.82M | 277.18M |
Cash Flow | |||||
| Free Cash Flow | -43.67M | -42.33M | -33.44M | -26.27M | -15.39M |
| Operating Cash Flow | -43.55M | -42.28M | -33.34M | -26.20M | -15.28M |
| Investing Cash Flow | 46.17M | 65.14M | -54.10M | -84.69M | -104.00K |
| Financing Cash Flow | 139.65M | -304.00K | -204.00K | 0.00 | 286.45M |
GH Research Technical Analysis
Positive
14.72
Price Trends
15.24
Negative
14.73
Negative
14.20
Positive
Market Momentum
-0.43
Positive
51.08
Neutral
45.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GHRS, the sentiment is Positive. The current price of 14.72 is above the 20-day moving average (MA) of 14.60, below the 50-day MA of 15.24, and above the 200-day MA of 14.20, indicating a neutral trend. The MACD of -0.43 indicates Positive momentum. The RSI at 51.08 is Neutral, neither overbought nor oversold. The STOCH value of 45.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GHRS.
GH Research Risk Analysis
GH Research disclosed 104 risk factors in its most recent earnings report. GH Research reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GH Research Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.92B | -5.25 | -43.17% | ― | -16.50% | 33.02% | |
57 Neutral | $1.18B | 440.78 | 1.15% | ― | 26.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $913.07M | ― | -16.30% | ― | ― | 8.16% | |
50 Neutral | $612.07M | -2.57 | -178.61% | ― | 647.13% | 26.79% | |
49 Neutral | $1.24B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
46 Neutral | $813.94M | -4.22 | -141.99% | ― | ― | 31.16% |
* Healthcare Sector Average
GHRS
GH Research
14.72
4.86
49.29%
RLAY
Relay Therapeutics
10.77
8.48
370.31%
TSHA
Taysha Gene Therapies
4.31
3.05
242.06%
SANA
Sana Biotechnology
3.05
1.68
122.63%
PHAR
Pharming Group
16.92
9.27
121.18%
PRME
Prime Medicine, Inc.
3.39
1.78
110.56%
GH Research Corporate Events
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
Mar 25, 2026
On March 25, 2026, GH Research PLC reported that full results from its randomized, double-blind, placebo-controlled Phase 2b trial of mebufotenin (GH001) in treatment-resistant depression have been published and peer-reviewed in JAMA Psychiatry. T...
GH Research to Join Stifel 2026 Virtual CNS Forum Fireside Chat
Mar 16, 2026
On March 16, 2026, GH Research PLC reported that it will take part in a fireside chat at the Stifel 2026 Virtual CNS Forum, a sector-focused event scheduled to be held online from March 17 to 18, 2026. The planned participation underscores the com...
GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone
Mar 5, 2026
GH Research PLC reported on March 5, 2026, that it completed a successful Phase 2b trial of its inhaled mebufotenin candidate GH001 in treatment-resistant depression in 2025, demonstrating rapid and durable remission rates with a strong safety pro...
GH Research to Present at RBC Capital Markets Psychedelics Symposium
Jan 22, 2026
On January 22, 2026, GH Research PLC announced it will participate in a virtual panel discussion at the RBC Capital Markets Psychedelics Symposium: A Trip Into The Future of Mental Health, highlighting its engagement with investors and industry st...
GH Research Showcases GH001 Depression Data at ACNP 2026 Mini‑Panel
Jan 15, 2026
On January 15, 2026, GH Research announced that it would present results from three clinical trials of its investigational antidepressant GH001 at a mini‑panel during the 64th American College of Neuropsychopharmacology annual meeting, held ...
GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026
Jan 13, 2026
On January 13, 2026, GH Research PLC announced that it would present clinical results from its Phase 2b GH001-TRD-201 trial in treatment-resistant depression at the Promising Targets Oral Session of the 64th American College of Neuropsychopharmaco...
GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting
Jan 8, 2026
On January 8, 2025, GH Research PLC reported that it will present new clinical data from its GH001-TRD-201 and GH001-BD-202 trials at the 64th American College of Neuropsychopharmacology annual meeting, to be held January 12–15, 2026, in Par...
GH Research Wins FDA Clearance to Advance GH001 for Treatment-Resistant Depression
Jan 5, 2026
On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational TRD therapy GH001, clearing the drug for clinical investigation in the United States and enabling U.S. patient enr...
GH Research Sets January 5 Update on IND Status and Phase 3 Plans for Lead TRD Drug GH001
Jan 2, 2026
On January 2, 2026, GH Research PLC announced that it plans to provide an update on the status of its Investigational New Drug Application (IND) for its lead candidate GH001 with the U.S. Food and Drug Administration, along with details on its glo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.